| abstract |
The present application relates to new benzimidazoles of the general formula in the R₁ to R₄ are as defined in claim 1, their tautomers and their salts, in particular for the pharmaceutical use of their physiologically tolerated salts, which have valuable pharmacological properties, since these are angiotensin antagonists, in particular angiotensin II antagonists, these compounds containing medicaments , their use and processes for their manufacture. |